grant

Accelerated Biological Aging and Immunosenescence as Drivers for Racial Disparities in Monoclonal Gammopathy of Undetermined Significance (MGUS)

Organization MAYO CLINIC ROCHESTERLocation ROCHESTER, UNITED STATESPosted 8 May 2026Deadline 30 Apr 2031
NIHUS FederalResearch GrantFY2026Aberrant ChromosomeAccess to CareAccountingAddressAffectAfrican AmericanAfrican American groupAfrican American individualAfrican American peopleAfrican American populationAfrican AmericansAfrican ancestryAfrican descentAfro AmericanAfroamericanAgeAgingAmericanBiologic FactorBiologicalBiological AgingBiological FactorsBiologyBlood Plasma CellCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCancersCategoriesCell BodyCell-Mediated Lympholytic CellsCellsCellular Immune FunctionChromosomal AberrationsChromosomal AbnormalitiesChromosomal AlterationsChromosome AberrationsChromosome AlterationsChromosome AnomaliesChromosome abnormalityChronicChronic stressClinicalClinical TrialsCytogenetic AberrationsCytogenetic AbnormalitiesCytolysisCytolytic T-CellCytotoxic T CellCytotoxic T-LymphocytesDescriptorDevelopmentDiagnosisDiseaseDisorderDisparitiesDisparityDrug TherapyEngraftmentEnvironmentEnvironmental FactorEnvironmental Risk FactorEthnic OriginEthnicityEuropeanEuropean ancestryEvaluationEvolutionExhibitsFavorable Clinical OutcomeFoundationsFutureGeneticGenomicsGoalsGrimAge clockGroups at riskHannum clockHealth Services AccessibilityHematopoietic Cell TumorHematopoietic MalignanciesHematopoietic NeoplasmsHematopoietic Neoplasms including LymphomasHematopoietic TumorHematopoietic and Lymphoid Cell NeoplasmHematopoietic and Lymphoid NeoplasmsHigh PrevalenceHorvath clockImmuneImmune MarkersImmune SurveillanceImmune systemImmunesImmunocompetentImmunologic MarkersImmunologic SurveillanceImmunosurveillanceIn VitroIncidenceIndividualIndolentInterventionIntervention StrategiesIntervention StudiesLinkLysisMGUSMalignant Hematopoietic NeoplasmMalignant NeoplasmsMalignant TumorMeasuresMediatingMiceMice MammalsModelingMonoclonal Gammopathy of Undetermined SignificanceMonoclonal Gammopathy of Unknown SignificanceMonoclonal gammopathy of uncertain significanceMultiple MyelomaMurineMusNewly DiagnosedOncogenesisOutcomePBMCPatientsPeople at riskPeripheralPeripheral Blood Mononuclear CellPersons at riskPharmacological TreatmentPharmacotherapyPhenoAge clocksPlasma CellsPlasma-Cell MyelomaPlasmacytesPopulationPopulation GroupPopulations at RiskPredispositionPrevalenceRaceRacesResearchRiskRoleStressSusceptibilityT-CellsT-LymphocyteT8 CellsT8 LymphocytesTestingTumor CellUnited StatesWest AfricanWorkaccelerated agingaccelerated biological ageaccelerated biological agingaccess to health careaccess to health servicesaccess to servicesaccess to treatmentaccessibility of health careaccessibility to health careaccessibility to health servicesage accelerationagesavailability of servicesbiologicbiological process of ageblood cancercancer of bloodcancer of the bloodcare accesschromosomal defectchromosome defectdevelopmentaldisparities in racedisparity due to racedisparity in healthdrug interventiondrug treatmentenvironmental riskenvironmental stressesenvironmental stressorepigenetic age clocksepigenetic clockepigenetic molecular clocksexhaustionexperiencefitnessfrailtyhealth care accesshealth care availabilityhealth care service accesshealth care service availabilityhealth disparityhealth service accesshealth services availabilityhigh riskhypoimmunityimmune competentimmune deficiencyimmune functionimmune microenvironmentimmune senescenceimmune-based biomarkersimmunodeficiencyimmunological biomarkersimmunological markersimmunosenescenceimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentinequality due to raceinequity due to raceinterestintervention researchinterventional researchinterventional studyinterventions researchkiller T celllife style interventionlifestyle interventionmalignancymethylation clockmouse modelmurine modelmyelomamyelomatosisneoplasm/cancerneoplastic cellnovelpharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticsplasmocyteprecancerprecancerouspremalignantpressurepreventpreventingpsychosocial stressespsychosocial stressorsrace based disparityrace based inequalityrace based inequityrace disparityrace related disparityrace related inequalityrace related inequityracialracial backgroundracial disparityracial inequalityracial inequityracial originracially unequalsenescence and its associated secretory phenotypesenescence associated secretomesenescence associated secretory factorssenescence associated secretory pathwaysenescence associated secretory phenotypesenescence associated secretory programsenescence associated secretory proteinssenescent associated secretomesenescent associated secretory phenotypeservice availabilitysocialsocial rolestressorthymus derived lymphocytetranslational studytreatment accesstumortumor immune microenvironmenttumor-immune system interactionstumorigenesis
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

PROJECT SUMMARY
Multiple myeloma (MM) is an incurable plasma cell malignancy and the most common blood cancer among

individuals who self-identify as African American, accounting for ~20% of newly diagnosed cases. The biological

factors contributing to the increased risk of MM and its precursor condition, monoclonal gammopathy of

undetermined…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →